Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry.

BACKGROUND Reports of the use of multiplex enzyme assay screening for Pompe disease, Fabry disease, Gaucher disease, Niemann-Pick disease types A and B, and Krabbe disease have engendered interest in the use of this assay in newborn screening. We modified the assay for high-throughput use in screening laboratories. METHODS We optimized enzyme reaction conditions and procedures for the assay, including the concentrations of substrate (S) and internal standard (IS), assay cocktail compositions, sample clean-up procedures, and mass spectrometer operation. The S and IS for each enzyme were premixed and bottled at an optimized molar ratio to simplify assay cocktail preparation. Using the new S:IS ratio, we validated the modified assay according to CLSI guidelines. Stability of the S, IS, and assay cocktails were investigated. Dried blood spots from 149 healthy adults, 100 newborns, and 60 patients with a lysosomal storage disorder (LSD) were tested using the modified assay. RESULTS In our study, the median enzyme activity measured in adults was generally increased 2-3-fold compared to the original method, results indicating higher precision. In the multiplex format, each of the 5 modified enzyme assays enabled unambiguous differentiation between samples from healthy individuals (adults and newborns) and the corresponding disease-specific samples. CONCLUSIONS The modified multiplex enzyme assay with premixed S and IS is appropriate for use in high-throughput screening laboratories.

[1]  M. Gelb,et al.  Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. , 2004, Clinical chemistry.

[2]  William,et al.  The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., and Vogelstein, B., eds., 8th ed., McGraw-Hill, New-York, 2001, 7012 p., $550.00) , 2004, Biochemistry (Moscow).

[3]  E. Schuchman,et al.  A fluorescence-based, high-throughput sphingomyelin assay for the analysis of Niemann-Pick disease and other disorders of sphingomyelin metabolism. , 2002, Analytical biochemistry.

[4]  R. Desnick,et al.  Identification and expression of a common missense mutation (L302P) in the acid sphingomyelinase gene of Ashkenazi Jewish type A Niemann-Pick disease patients , 1992 .

[5]  P. Kishnani,et al.  Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots. , 2007, Molecular genetics and metabolism.

[6]  N. Chamoles,et al.  Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[7]  W. Hwu,et al.  Newborn Screening for Pompe Disease: Synthesis of the Evidence and Development of Screening Recommendations , 2007, Pediatrics.

[8]  K. Ohno.  [Niemann-Pick disease types A and B]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.

[9]  Yuan-Tsong Chen,et al.  Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid α-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease , 2006, Genetics in Medicine.

[10]  E. Schuchman,et al.  An enzymatic assay for quantifying sphingomyelin in tissues and plasma from humans and mice with Niemann-Pick disease. , 2001, Analytical biochemistry.